• Vaccine Name: T. cruzi DNA vaccine encoding TSA-1, ASP-1, ASP-2
• Target Pathogen: Trypanosoma cruzi
• Target Disease: Chagas disease
• Vaccine Ontology ID: VO_0004374
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• TSA-1 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pCMVI.UBF3/2 expressed TSA-1 (Garg and Tarleton, 2002).
  • Detailed Gene Information: Click Here.
• amastigote surface protein-2 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pCMVI.UBF3/2 expressed ASP-2 cDNA (Garg and Tarleton, 2002).
  • Detailed Gene Information: Click Here.
• ASP1 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pCMVI.UBF3/2 expressed ASP-1 cDNA (Garg and Tarleton, 2002).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000220
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: Immunization of mice with plasmids encoding ASP-1, ASP-2, or TSA-1 elicited poor antigen-specific cytotoxic-T-lymphocyte (CTL) activity and T. cruzi-specific antibody responses. Codelivery of interleukin-12 and granulocyte-macrophage colony-stimulating factor plasmids with antigen-encoding plasmids resulted in a substantial increase in CTL activity and antibody production and in increased resistance to T. cruzi infection (Garg and Tarleton, 2002).
• Efficacy: Immunization with this mixture of ts-encoding plasmids elicited moderate parasite-specific antibody responses and substantial CTL activity and subsequently provided significant resistance to T. cruzi infection. In conclusion, genetic vaccines composed of ASP-1, ASP-2, and TSA-1 provide partial protection from lethal T. cruzi infection (Garg and Tarleton, 2002).